



Atezolizumab 1200 Maintenance, Non-Small Cell Lung Cancer

Protocol-ID: 1272 V1.1 (Basic), ATEZ1200 maint., NSCLC

Indication(s)

- Lung Carcinoma, Non-Small Cell; ICD-10 C34.- non-squamous

Cycles

Cycle length 21 days, recommended cycles: 10

Protocol sequences

- [IMpower130: ATEZ1200/NPAC100/CRBP6. NSCLC \(PID1238\) -/- ATEZ1200 Erh. \(PID1272\)](#)

References

- West H, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. PMID: 31122901. [[PMID](#)]

Recommendations

- 01/2023: [European Society for Medical Oncology](#)
- 02/2024: [National Comprehensive Cancer Network](#)

Important notice

The copyrighted protocols are treatment recommendations. The information contained in this compilation on cytostatic drugs, concomitant medication and other therapeutic procedures, as well as dosage and application information, is continuously reviewed with all due care by the authors and editors involved. Nevertheless, the publishers and authors do not assume any liability for the correctness - also with regard to possible printing errors.

The protocols may not be changed in terms of content. Any further use of the protocols in physical or non-physical form, such as copying, distribution, disclosure, export to other media, or publication, even in excerpt form, is not permitted.

Diagnosis, indication for therapy and treatment of malignant diseases must be carried out in each individual case by the hematologist and oncologist on his or her own responsibility. The treating physician is obligated to this personal responsibility to weigh in each case before a diagnostic or therapeutic measure, indication, contraindications, dosage and application under consideration of the specialized information or other documents of the manufacturers. This applies in particular to rarely used preparations or preparations that are new to the market.



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 08.07.2025